NCT00992355

Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery

Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: Veroia General Hospital · Academic / Other
• Sex: All
• Age: 55 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled trial compares two regimens of topical therapy: * tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day * combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day. The topical treatment is administered for 28 days after phacoemulsification. Patients are independently assessed by two ophthalmologists. On day 28, patients are evaluated for * corneal edema * conjunctival redness * anterior chamber reaction. Moreover, the cases necessitating continuation of treatment are compared in the two groups on day 28 and 42.

Conditions

• Cataract

Interventions

Type	Name	Description
DRUG	Tobramycin 0.3% - Dexamethasone 0.1%
DRUG	Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-03-01
• Completion: 2009-04-01
• First posted: 2009-10-09
• Last updated: 2009-10-09

Locations

1 site across 1 country: Greece